Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Adcentrx Adds $13 Million to A+ Round for Novel Antibody Drug Conjugates

publication date: Dec 6, 2023

Adcentrx Therapeutics, a San Diego-Shanghai ADC biotech, added $13 million to the Series A+ funding announced earlier this year, bringing the total to $51 million for the round. The company’s lead drug is an ADC targeting Nectin-4, a cell surface adhesion protein over-expressed in multiple human cancers and associated with poor disease prognosis. ADRX-0706 is currently being tested in a US Phase Ia/b clinical trial. Adcentrx said the additional funds will extend its runway into 2025 and accelerate development of the company’s portfolio. The Series A+ extension included participation from Quan Capital and Partners Investment. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital